Open AccessTumor-associated myeloid-derived suppressor cells as a potential biomarker for prognostication of response in treatment of diffuse large cell lymphoma.
Author(s) -
Kalyan Kusum Mukherjee,
Sukanya Dhar,
Rajib Bhattacharjee,
Subhadip Das,
Mohona Chakraborty,
Shayani Bhanja,
Sarbari Ghosh,
Madhurima Sarkar,
Shayani Dasgupta,
Dipanwita Ghosh,
Anamika Bose,
Rathindranath Baral
Publication year - 2019
Publication title -
journal of global oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.002
H-Index - 17
ISSN - 2378-9506
DOI - 10.1200/jgo.2019.5.suppl.30
Subject(s) - medicine , cd33 , biomarker , diffuse large b cell lymphoma , lymphoma , foxp3 , cd8 , chop , oncology , immune system , cd20 , immunology , cancer research , biology , stem cell , biochemistry , genetics , cd34
30 Background: NHL is a type of lymphoma either B or T cell origin. However, 85% is of B cell type, especially diffuse large B cell lymphoma (DLBCL) with CD20+ in nature. Standard of care of CD20+DLBCL is R-CHOP 6 to 8 cycles and 66% patients generally respond to this treatment. Remaining 34% is still unresponsive to R-CHOP. Thus, establishment of a biomarker is required to intensify the treatment.Out of different scope of biomarker development, alterations in immune cellular components within tumor microenvironment may be tried as a potential biomarker to assess the possibility of occurrence of residual disease and relapse within 2 years for the DLBCL patients with 6-8 cycles of R-CHOP. Methods: : Selected CD20 + DLBCL patients (n=51) were treated with 6-8 cycles of R-CHOP and included in the present study with their informed consent. A panel of immune cells, like, T (CD4 + , CD8 + )-cells, regulatory T (CD4 + CD25 + FoxP3)-cells, MDSCs (CD33 + CD11b + CD14 -/+ ), memory T (CD8 + CD45RO + )-cells and multidrug resistance (MDR) phenotypes (P-gp, MRP1), were studied by flow-cytometry and RT-PCR at different phases of treatment. Results: Within 51 selected patients, 9 were disease free and 11 patients exhibited stable disease for 2 years following the completion of treatment. Rest of the patients (n=31) showed relapse in different time periods. Among several immune cells studied, CD33 + CD11b + MDSCs were remarkably elevated in high-grade residual-and-relapsed DLBCL patients compared to non-relapsed patients and normal healthy individuals. CD33 + CD14 + monocytic, but not CD33 + CD14 - granulocytic MDSCs were mostly increased in relapsed patients than control. Moreover, expression of MDR phenotypic markers was found to be elevated in these relapsed patients. Among relapsed patients CD8 + CD45RO + memory T cells were increased, however, these cells are mostly corrupted in nature. Conclusions: Observed correlation between increased monocytic MDSCs with the occurrence of residual disease and/or relapse suggests monocytic MDSCs might be a potential biomarker for prediction of residual-and-relapsed DLBCL patients.